Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
1(100.0%)
1Total
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06908369Active Not Recruiting

Cardiac Symptoms in Patients With Treated Graves' Disease

Role: lead

NCT02969200Completed

Fabry: Renal Function During Long-term ERT by 51Cr-EDTA Clearance

Role: lead

NCT02908724Completed

Cardiac Involvement in Adult Patients With Fabry Disease; Relation to Enzyme Replacement Therapy

Role: lead

NCT02282150Phase 4Unknown

Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism

Role: lead

All 4 trials loaded